ABBV raises 2018 HCV sales guidance to $3.5B (from $2.5B). Almost all of this will come from Mavyret (which accounted for $850M of the $919M HCV sales logged during 1Q18).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”